For the Quarter Ending June 2026
Aciclovir Prices in North America
- In the United States, the Aciclovir Price Index rose quarter-over-quarter in Q2 2026, driven by significant producer inflation and increased production costs.
- Aciclovir production costs increased in Q2 2026, influenced by a 6.5% year-over-year Producer Price Index in May 2026.
- Demand for Aciclovir was supported by robust U.S. pharmaceutical market growth and high healthcare expenditure in Q2 2026.
- Industrial production expanded by 1.7% year-over-year in May 2026, supporting stable supply chains for Aciclovir manufacturing.
- A low 4.2% unemployment rate in June 2026 bolstered consumer spending, indirectly supporting the pharmaceutical market.
- U.S. chemical exports rose in 2026, while imports declined, impacting overall chemical trade flows during the period.
- Natural gas inventories remained above the five-year average at the end of June 2026, limiting upward energy price pressures.
- Brent crude oil spot prices averaged lower in June 2026, declining from an April 2026 peak, influencing energy costs.
Why did the price of Aciclovir change in June 2026 in North America?
- Producer Price Index rose 6.5% in May 2026, increasing Aciclovir raw material and manufacturing costs.
- Retail sales grew 6.9% year-over-year in May 2026, supporting overall healthcare demand.
- Higher freight rates in early 2026, due to geopolitical developments, elevated Aciclovir transportation.
Aciclovir Prices in APAC
- In China, the Aciclovir Price Index rose quarter-over-quarter in Q2 2026, driven by increasing production costs.
- Aciclovir production costs increased as the Producer Price Index rose 4.1% year-over-year in June 2026.
- Demand for Aciclovir faced headwinds as retail sales declined 0.6% year-over-year in May 2026.
- Consumer confidence remained pessimistic at 89.9 in May 2026, impacting discretionary spending.
- The Manufacturing Index expanded in June 2026, supporting the industrial base for Aciclovir supply.
- Industrial production grew 4.5% year-over-year in May 2026, ensuring stable supply chain capabilities.
- Beijing's plans to increase electricity prices in June 2026 contributed to rising Aciclovir production expenses.
- Crude oil and coal import disruptions in April and May 2026 led to elevated energy feedstock costs.
- China's chemical exports continued to rise in May 2026, with volumes reaching a record high.
Why did the price of Aciclovir change in June 2026 in APAC?
- Rising input costs, with Producer Price Index increasing 4.1% year-over-year in June 2026.
- Weakened consumer demand, as retail sales declined 0.6% year-over-year in May 2026.
- Increased electricity prices for energy-intensive sectors in June 2026 impacted manufacturing expenses.
Aciclovir Prices in Europe
- In Germany, the Aciclovir Price Index rose quarter-over-quarter in Q2 2026, driven by rising production costs and supply disruptions.
- Aciclovir production costs increased during Q2 2026, influenced by a 2.2% rise in producer prices in May 2026.
- Demand for prescription Aciclovir remained robust in Q2 2026, supported by Germany's growing pharmaceutical market.
- Energy and raw material costs for Aciclovir manufacturing rose in Q2 2026, with significant energy inflation in April 2026.
- Chemical feedstock inventories tightened in Q2 2026 due to reported shortfalls, impacting Aciclovir supply.
- The Manufacturing Index trended contracting in June 2026, indirectly affecting Aciclovir supply chain efficiency.
- Aciclovir's over-the-counter demand faced slight pressure in Q2 2026 due to weakened consumer sentiment.
- Overall inflationary pressures, indicated by a 2.3% CPI year-over-year in June 2026, increased Aciclovir operational costs.
- The Aciclovir Price Index is forecast to remain elevated due to persistent cost pressures and ongoing geopolitical supply risks.
Why did the price of Aciclovir change in June 2026 in Europe?
- Rising producer prices, up 2.2% in May 2026, increased Aciclovir raw material and input costs.
- Significant energy price inflation in April 2026 elevated Aciclovir production expenses in Germany.
- Intensified supply chain disruptions during Q2 2026 constrained Aciclovir availability in Europe.
For the Quarter Ending March 2026
Aciclovir Prices in North America
- In United States, the Aciclovir Price Index rose quarter-over-quarter in Q1 2026, driven by elevated production costs.
- During March 2026, retail sales grew 4.0% year-over-year and CPI rose 3.3%, supporting the Aciclovir Demand Outlook.
- In March 2026, PPI increased 4.0% year-over-year and industrial production rose 0.7%, elevating the Aciclovir Production Cost Trend.
- During March 2026, unemployment reached 4.3% and consumer confidence hit 91.8, maintaining insured patient Aciclovir demand.
- The Manufacturing Index expanded in March 2026, indicating robust industrial activity for Aciclovir active pharmaceutical ingredients.
- Methanol feedstock costs and Brent crude oil surged in March 2026, increasing upstream Aciclovir synthesis expenses.
- Conversely, acetic acid and dimethylformamide precursor costs plummeted or stabilized during January-March 2026, partially offsetting expenses.
- Aciclovir import volumes fluctuated and inventory cycles lengthened in Q1 2026 due to new tariff implementations.
- The Aciclovir Price Forecast indicated upward pressure throughout Q1 2026 as suppliers navigated shifting regulatory frameworks.
Why did the price of Aciclovir change in March 2026 in North America?
- Aciclovir production costs spiked in March 2026 due to surging upstream methanol and energy inflation.
- Tariff implementations in January 2026 reshaped supply chains, increasing Aciclovir active pharmaceutical ingredient import expenses.
- Strong retail sales in March 2026 sustained robust consumer demand for Aciclovir despite rising prices.
Aciclovir Prices in Europe
- In Germany, the Aciclovir Price Index rose quarter-over-quarter in Q1 2026, driven by severe domestic supply shortages.
- Consumer inflation reached 2.7% in March 2026, while producer prices declined by 0.2% during the same period.
- The Manufacturing Index expanded in March 2026, despite stagnant industrial production recorded at 0.0% in February 2026.
- Retail sales grew 0.7% and unemployment remained stable at 4.2% in February 2026, supporting Aciclovir Demand Outlook.
- Consumer confidence fell to -24.7 in March 2026, negatively impacting premium over-the-counter Aciclovir demand across the region.
- The Aciclovir Production Cost Trend increased in March 2026 as naphtha, methanol, and ethylene precursor prices surged.
- Active pharmaceutical ingredient imports became severely constrained in Q1 2026, causing domestic Aciclovir stockpiles to dwindle rapidly.
- The Aciclovir Price Forecast indicated upward pressure in March 2026 due to elevated demand for off-patent medicines.
Why did the price of Aciclovir change in March 2026 in Europe?
- Naphtha and methanol feedstock costs surged significantly in March 2026, driving up Aciclovir production expenses.
- Essential medicine availability deteriorated in March 2026, exacerbating domestic supply shortages for off-patent antiviral treatments.
- Shipping disruptions severely constrained active pharmaceutical ingredient imports from Asia into Europe during March 2026.
Aciclovir Prices in APAC
- In China, the Aciclovir Price Index rose quarter-over-quarter in Q1 2026, driven by rising raw material costs.
- The Aciclovir Production Cost Trend increased in March 2026 as national producer prices rose 0.5% year-over-year.
- Consumer inflation rose 1.0% while retail sales grew 1.7% in March 2026, impacting retail Aciclovir sales.
- The Aciclovir Demand Outlook softened in March 2026 because the urban unemployment rate reached exactly 5.4%.
- Consumer confidence remained low at 86.0 in Q1 2026, while domestic Aciclovir API inventories tightened significantly.
- Industrial production grew 5.7% in March 2026, ensuring ample domestic supply capabilities for bulk Aciclovir APIs.
- The Manufacturing Index expanded in March 2026, aligning with surged pharmaceutical API export volumes in February 2026.
- The Aciclovir Price Forecast reflected upward momentum in Q1 2026 as domestic guanine feedstock demand surged.
Why did the price of Aciclovir change in March 2026 in APAC?
- Producer prices rose 0.5% in March 2026, directly increasing Aciclovir active pharmaceutical ingredient production costs.
- Demand for essential guanine and guanosine feedstocks surged significantly during the Q1 2026 reporting period.
- Domestic small-molecule API inventories tightened in Q1 2026 while pharmaceutical exports surged in February 2026.
For the Quarter Ending December 2025
Aciclovir Prices in North America
- In United States, the Aciclovir Price Index rose in Q4 2025, driven by rising production costs and tightening regional supply.
- Aciclovir production costs increased from a 2.7% CPI rise year-over-year in December 2025, affecting raw materials and labor.
- Input costs for Aciclovir manufacturing rose, with PPI increasing 3.0% year-over-year in November 2025.
- North American ammonia feedstock costs trended upward in October 2025, impacting Aciclovir production expenses.
- Natural gas prices, a key energy input for Aciclovir, surged in December 2025 due to a cold snap.
- Aciclovir demand was supported by a 3.3% retail sales increase and 89.1 consumer confidence in December 2025.
- A 4.4% unemployment rate in December 2025 indicated a strong labor market, bullish for Aciclovir demand.
- Industrial production increased 2.0% year-over-year in December 2025, supporting Aciclovir supply stability.
- The Aciclovir Price Forecast suggests continued upward pressure from persistent cost increases and supply constraints.
Why did the price of Aciclovir change in December 2025 in North America?
- Natural gas prices, a key energy input, surged in December 2025 from a cold snap.
- US methanol feedstock costs declined in December 2025 from year-end inventory liquidation.
- CPI increased 2.7% year-over-year in December 2025, raising Aciclovir production expenses.
Aciclovir Prices in APAC
- In China, the Aciclovir Price Index remained stable in Q4 2025, influenced by subdued consumer inflation of 0.8% in December 2025.
- Aciclovir production costs declined in December 2025, as the producer price index fell by 1.9% year-over-year.
- Aciclovir demand outlook was tempered in Q4 2025, with retail sales growing only 0.9% year-over-year in December 2025.
- The Manufacturing Index expanded in December 2025, supporting stable supply chains for Aciclovir production.
- Industrial production grew by 5.2% year-over-year in December 2025, indicating robust manufacturing activity.
- High guanine raw material costs continued to constrain Aciclovir production capacity during Q4 2025.
- China's pharmaceutical market maintained healthy growth in Q4 2025, driven by post-pandemic recovery.
- Healthcare financing activity strongly recovered in Q4 2025, positively impacting the Aciclovir market.
- Aciclovir prices were assessed at USD 54840 / MT in Q4.
Why did the price of Aciclovir change in December 2025 in APAC?
- Producer prices declined by 1.9% year-over-year in December 2025, reducing Aciclovir manufacturing input costs.
- Subdued consumer price index at 0.8% year-over-year in December 2025 indicated weak demand-side inflation.
- High guanine raw material costs continued to constrain production capacity for Aciclovir in Q4 2025.
Aciclovir Prices in Europe
- In Germany, the Aciclovir Price Index remained stable or slightly declined in Q4 2025, influenced by lower industrial input costs in December 2025.
- Aciclovir production costs faced upward pressure from high energy and raw material costs throughout Q4 2025.
- The Producer Price Index declined -2.5% year-on-year in December 2025, indicating reduced industrial input costs.
- Aciclovir demand was supported by moderate pharmaceutical market growth and substantial prescription volumes in Q4 2025.
- Retail sales grew 1.1% year-on-year in November 2025, supporting over-the-counter Aciclovir demand.
- Consumer confidence declined to -17.5 in December 2025, and a 6.2% unemployment rate dampened demand.
- Moderate inflation, with CPI at 1.8% year-on-year in December 2025, increased Aciclovir operational costs.
- German chemical production declined in Q4 2025, with capacity utilization at a low 70% during 2025.
- Industrial production grew 0.8% year-on-year in October 2025, indicating stable, slow economic activity.
- Why did the price of Aciclovir change in December 2025 in Europe?
- Production costs were influenced by persistently high energy and raw material costs in Q4 2025.
- A -2.5% Producer Price Index year-on-year in December 2025 indicated lower industrial input costs.
- Demand for generics like Aciclovir was supported by moderate pharmaceutical market growth in Q4 2025.
For the Quarter Ending September 2025
Aciclovir Prices in North America
- In the United States, the Aciclovir Price Index rose quarter-over-quarter in Q3 2025, influenced by rising producer costs.
- Aciclovir production costs faced upward pressure from a 2.6% PPI increase in August 2025 and 3.0% CPI in September 2025.
- Demand for Aciclovir was supported by a 5.42% retail sales increase and low 4.3% unemployment in September 2025.
- The Aciclovir Price Forecast suggests continued upward pressure due to persistent inflation and robust consumer spending.
- Overall pharmaceutical market demand is anticipated to rise in 2025, driving the Aciclovir Demand Outlook.
- Wholesale inventories declined slightly in August 2025, while industrial production increased 0.1% in September 2025.
- US natural gas prices stabilized and moderated during Q3 2025, easing some Aciclovir production cost pressures.
- Consumer confidence declined to 94.2 in September 2025, potentially tempering demand for OTC Aciclovir products.
Why did the price of Aciclovir change in September 2025 in North America?
- Rising PPI (2.6% in August 2025) increased Aciclovir manufacturing costs.
- Strong retail sales, up 5.42% in September 2025, supported Aciclovir demand and pricing power.
- Consumer confidence declined to 94.2 in September 2025, potentially limiting demand for discretionary Aciclovir purchases.
Aciclovir Price in APAC
- In China, the Aciclovir Price Index fell quarter-over-quarter in Q3 2025, influenced by declining producer prices.
- Aciclovir production costs faced downward pressure as the Producer Price Index declined 2.3% year-on-year in September 2025.
- Demand outlook for Aciclovir was challenged by a 0.3% year-on-year decrease in the Consumer Price Index in September 2025.
- The Manufacturing Index was contracting in September 2025, suggesting a slowdown in overall industrial activity.
- Aciclovir demand faced headwinds from a 5.2% unemployment rate and low consumer confidence (89.6 index) in September 2025.
- Industrial production expanded 6.5% year-on-year in September 2025, supporting a stable environment for Aciclovir supply.
- General chemical overcapacity persisted in China during Q3 2025, contributing to stable production costs for Aciclovir.
- Retail sales increased 3.0% year-on-year in September 2025, indicating healthy consumer spending despite other economic pressures.
- China's chemical production capacity continued to expand in Q3 2025, maintaining higher operating rates for self-sufficiency.
- Petrochemical feedstock prices, including benzene, remained relatively stable in early Q3 2025, impacting Aciclovir input costs.
Why did the price of Aciclovir change in September 2025 in APAC?
- Producer Price Index declined 2.3% year-on-year in September 2025, reducing Aciclovir manufacturing costs.
- Consumer Price Index decreased 0.3% year-on-year in September 2025, indicating broader deflationary pressures.
- Manufacturing Index was contracting in September 2025, signaling a slowdown in industrial activity and demand.
Aciclovir Price in Europe
- In Germany, the Aciclovir Price Index remained stable in Q3 2025, influenced by rising consumer inflation and declining producer prices.
- Aciclovir production costs trended lower in September 2025 due to a 1.7% year-over-year decline in producer prices.
- Demand for Aciclovir saw moderate growth in Q3 2025, supported by Germany's aging population and chronic disease prevalence.
- A contracting Manufacturing Index in Q3 2025 and 1.0% industrial production decline impacted Aciclovir supply chain.
- Elevated wholesale electricity prices in Q3 2025, driven by higher natural gas costs, sustained Aciclovir manufacturing expenses.
- Retail sales increased 0.2% in September 2025, mildly supporting over-the-counter Aciclovir demand.
- Stable unemployment at 6.3% in September 2025 suggests potential affordability barriers for Aciclovir consumers.
- Weakening international business and US tariffs in July 2025 negatively impacted German chemical and pharmaceutical trade.
Why did the price of Aciclovir change in September 2025 in Europe?
- Lower producer prices, down 1.7% year-over-year in September 2025, reduced Aciclovir manufacturing costs.
- Elevated wholesale electricity prices in Q3 2025, from natural gas costs, sustained Aciclovir operational expenses.
- Contracting Manufacturing Index in Q3 2025 and declining industrial production impacted Aciclovir supply chain.
